URGN on Nasdaq

UroGen Pharma Ltd.

We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with ImmunoGen Inc., Theravance Biopharma, Inc. or ZEVRA THERAPEUTICS, INC., or pick any stock.

  • TickerURGN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersL31
  • Incorporated inIsrael2
  • Business address9 Ha'Ta'Asiya St, Ra'Anana, L3 43650072
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our approved products Jelmyto (mitomycin) for pyelocalyceal solution and Zusduri (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer (“low-grade UTUC”) and recurrent low-grade intermediate risk non-muscle invasive bladder cancer (“low-grade intermediate risk…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

88.7%Gross margin4
-113.7%Operating margin4
-139.8%Net margin4
21.4%Revenue growth, 20254
-$162.7MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Jelmyto brought in 86% of the revenue UroGen Pharma Ltd. broke down this way in fiscal 2025.

  1. Jelmyto$94.0M486%up 4% from 2024
  2. Zusduri$15.8M414%
Products and services by year
Products and services20242025
Jelmyto$90.4M$94.0M
Zusduri$0$15.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue5¢$12.4M
  • Research and development29¢$67.1M
  • Selling, general and admin66¢$155.1M
  • Income tax0¢$78.0K

Out of $109.8M in revenue.4 The company lost money this year.

Financial statements

Revenue567894$109.8M in 2025+609833% since 2019
0$50.0M$100.0M$150.0M2019: $18.0K$18.0K20192020: $11.8M$11.8M2020+65450%2021: $48.0M$48.0M2021+307%2022: $64.4M$64.4M2022+34%2023: $82.7M$82.7M2023+29%2024: $90.4M$90.4M2024+9%2025: $109.8M$109.8M2025+21%
Gross profit567894$97.3M in 2025+540683% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $18.0K$18.0K20192020: $10.8M$10.8M2020+59844%2021: $42.9M$42.9M2021+297%2022: $56.7M$56.7M2022+32%2023: $73.4M$73.4M2023+29%2024: $81.5M$81.5M2024+11%2025: $97.3M$97.3M2025+19%
Operating income567894-$124.9M in 2025+14% since 2019
-$150.0M-$100.0M-$50.0M02019: -$109.5M-$109.5M20192020: -$126.7M-$126.7M2020+16%2021: -$92.3M-$92.3M2021−27%2022: -$79.0M-$79.0M2022−14%2023: -$65.5M-$65.5M2023−17%2024: -$96.8M-$96.8M2024+48%2025: -$124.9M-$124.9M2025+29%
Net income567894-$153.5M in 2025+46% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$105.1M-$105.1M20192020: -$128.5M-$128.5M2020+22%2021: -$110.8M-$110.8M2021−14%2022: -$109.8M-$109.8M2022−1%2023: -$102.2M-$102.2M2023−7%2024: -$126.9M-$126.9M2024+24%2025: -$153.5M-$153.5M2025+21%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenue$109.8M$90.4M
Cost of revenue$12.4M$8.9M
Gross profit$97.3M$81.5M
Research and development expenses$67.1M$57.1M
Selling, general and administrative expenses$155.1M$121.2M
Operating loss-$124.9M-$96.8M
Financing on prepaid forward obligation-$18.5M-$23.4M
Interest expense on long-term debt-$15.3M-$12.5M
Interest and other income, net$5.3M$8.7M
Loss before income taxes-$153.4M-$124.0M
Income tax expense-$78.0K-$2.8M
Net Loss-$153.5M-$126.9M
Unrealized income (loss) on investments-$37.0K$44.0K
Comprehensive Loss-$153.5M-$126.8M
Net loss per ordinary share - basic and diluted (in dollars per share)-$3.19-$2.96
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)48.1M shares42.9M shares

Compare UroGen Pharma Ltd. with another company

Leadership

Who has led UroGen Pharma Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ron Bentsur2019

Chief financial officer

  1. Peter P. Pfreundschuh2019–2020
  2. Molly Henderson2020–2022
  3. Chris Degnan2024–now

Chief operating officer

  1. Stephen Mullennix2019–2020
20202025
Board members and other officers (11)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerDon Kim named Aug 14, 202327
  • Executive Officer, DirectorElizabeth Barrett named Aug 14, 202327
  • Executive OfficerJason A. Smith named Aug 14, 202327
  • DirectorJames A. Robinson, Jr. named Aug 14, 202327
  • DirectorLeana Wen, M.D., MSc named Aug 14, 202327

Timeline

  1. Jan 10, 2019New chief executive Ron Bentsur becomes CEO12

Filings

303 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 50 major events, 121 insider forms, 53 large holders, 1 private raises, 55 other. The latest 20:

  1. Oct 9, 2026144 EDGAR
  2. Oct 9, 20264 EDGAR
  3. Sep 9, 2026144 EDGAR
  4. Sep 9, 2026144 EDGAR
  5. Sep 9, 20264 EDGAR
  6. Sep 9, 20264 EDGAR
  7. Aug 28, 20264 EDGAR
  8. Aug 24, 20264 EDGAR
  9. Aug 20, 20268-K EDGAR
  10. Aug 20, 2026144 EDGAR
  11. Aug 12, 2026SCHEDULE 13G/A EDGAR
  12. Aug 5, 202610-Q EDGAR
  13. Aug 5, 20268-K EDGAR
  14. Jul 10, 20264 EDGAR
  15. Jul 9, 2026144 EDGAR
  16. Jun 24, 20264 EDGAR
  17. Jun 24, 20264 EDGAR
  18. Jun 24, 20264 EDGAR
  19. Jun 24, 20264 EDGAR
  20. Jun 24, 20264 EDGAR

The 303 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

45 open-market trades by officers, directors and large owners since October 2021: 1 buys and 44 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 8, 2026Schoenberg MarkChief Medical OfficerSale871$42.92$37.4KForm 4
Sep 8, 2026Smith Jason DrewGeneral CounselSale1,519$42.54$64.6KForm 4
Aug 20, 2026Schoenberg MarkChief Medical OfficerSale60,677$47.05$2.9MForm 4
Jul 9, 2026Schoenberg MarkChief Medical OfficerSale10,000$40.00$400.0KForm 4
Jun 22, 2026Schoenberg MarkChief Medical OfficerSale10,000$35.01$350.1KForm 4
Jun 8, 2026Schoenberg MarkChief Medical OfficerSale5,222$27.30$142.6KForm 4
May 8, 2026Schoenberg MarkChief Medical OfficerSale10,000$30.00$300.0KForm 4
Feb 3, 2026Smith Jason DrewGeneral CounselSale7,479$19.69$147.3KForm 4
Feb 3, 2026Schoenberg MarkChief Medical OfficerSale7,373$19.69$145.2KForm 4
Nov 19, 2025Schoenberg MarkChief Medical OfficerSale10,000$25.00$250.0KForm 4
Oct 8, 2025Degnan ChrisChief Financial OfficerSale2,203$16.85$37.1KForm 4
Sep 8, 2025Schoenberg MarkChief Medical OfficerSale871$19.11$16.6KForm 4
Sep 8, 2025Smith Jason DrewGeneral CounselSale1,520$19.11$29.0KForm 4
Aug 11, 2025Schoenberg MarkChief Medical OfficerSale10,000$17.69$176.9KForm 4
Jul 28, 2025Smith Jason DrewGeneral CounselSale7,522$19.14$144.0KForm 4
Jul 28, 2025Schoenberg MarkChief Medical OfficerSale5,149$19.14$98.6KForm 4
Jun 9, 2025Schoenberg MarkChief Medical OfficerSale5,162$7.37$38.0KForm 4
Jan 31, 2025Schoenberg MarkChief Medical OfficerSale4,551$11.14$50.7KForm 4
Jan 31, 2025Smith Jason DrewGeneral CounselSale7,379$11.14$82.2KForm 4
Sep 9, 2024Schoenberg MarkChief Medical OfficerSale859$13.08$11.2KForm 4

All 45 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 26, 2023Raised $120 million in a private offering of equity Form D: 8 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47